Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00923780 · ClinicalTrials.gov registry record
Evaluation of Blood Vessel Formation in Endocrine Tumors
A clinical trial of Lesions, sponsored by National Cancer Institute (NCI).
- Completed
- Registry status
- 400
- Enrollment target
- 1
- Study location
NCT00923780 is a study of Lesions that has completed, run by National Cancer Institute (NCI). The registered enrollment target is 400 participants. The trial reports 1 study location across 1 state.
The verdict
NCT00923780, a study of Lesions, has completed, sponsored by National Cancer Institute (NCI).
- COMPLETED
- Registry status
- 400 participants
- Enrollment target
- 1
- Study location
Study Summary
Background: * Tumors depend on blood vessels to provide the nourishment that allows them to grow. * Thyroid, parathyroid, adrenal gland and pancreatic neuroendocrine tumors are among the tumors that contain the most blood vessels. Thus, endocrine tumors are important for the study of new blood vessel formation in tumors. Objectives: -To obtain tissues from endocrine tumors for examination to determine how they differ from normal tissue. Eligibility: -Patients who are scheduled for surgery to remove an endocrine tumor, those in or around the thyroid, parathyroid, adrenal gland, pancreas, or any neuroendocrine tissue. Design: * Tissues will be obtained from patients during surgery to remove thyroid, parathyroid, adrenal, pancreas, or neuroendocrine tumors. * About 400 patients will be enrolled in the study over a period of 5 years.
Conditions Studied
Study Locations (1)
Maryland
- National Institutes of Health Clinical Center, 9000 Rockville Pike - Bethesda
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 400 participants |
| Start Date | 2007-01-05 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00923780
The ClinicalTrials.gov registry entry for NCT00923780 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 400 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is National Cancer Institute (NCI), which has 3,257 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Lesions appearing as the primary indexed condition, and to 0 interventions.
NCT00923780 reports 1 study location spanning 1 distinct geographic area - top geographies include Maryland.
Frequently Asked Questions
What is clinical trial NCT00923780 about?
NCT00923780 is a clinical study titled "Evaluation of Blood Vessel Formation in Endocrine Tumors". Background: * Tumors depend on blood vessels to provide the nourishment that allows them to grow. * Thyroid, parathyroid, adrenal gland and pancreatic neuroendocrine tumors are among the tumors that contain the most blood vessels. Thus, endocrine tumors are important for the study of new blood vess...
What is the current status of trial NCT00923780?
This trial is currently completed. The enrollment target is 400 participants. The study started on 2007-01-05.
What conditions does trial NCT00923780 study?
This clinical trial studies the following conditions: Lesions.
Who is sponsoring clinical trial NCT00923780?
This trial is sponsored by National Cancer Institute (NCI), which has 3,257 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00923780 being conducted?
This trial has 1 study location across Maryland. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.